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 Abstract 
Background The p53 protein in mesenchymal stem cells (MSCs) regulates differentiation to 
osteogenic or adipogenic lineage. Because p53 function is depressed in most malignancies, if 
MSCs in malignancy also have the p53 hypofunction, differentiation therapy to osteogenic or 
adipogenic lineage may be an effective treatment. We therefore wished to begin to explore this 
idea by evaluating atypical lipomatous tumors/well-differentiated liposarcoma (ALT/WDL) cells, 
because murine double minute 2 (MDM2) gene amplification, which leads to p53 hypofunction, 
is found in almost all ALT/WDLs.  
Questions/purposes We compared osteogenic and adipogenic differentiation potency between 
MSCs isolated and cultured from normal adipose tissues and ALT/WDLs from the same patients. 
Methods During tumor resections in six patients with ALT/WDL, we analyzed 3 ml
 
of tumor, 
and for comparison, we harvested a similar amount of normal-appearing subcutaneous adipose 
tissue from an area remote from the tumor for comparison. Adipogenic differentiation potency 
was quantitatively assessed using spectrometry after Oil Red O staining. Osteogenic 
differentiation potency was semiquantitatively assessed by measuring a specific colored area 
after alkaline phosphatase (ALP) and alizarin red S staining. ALP is related to preosseous 
cellular metabolism, and alizarin red is related to calcium deposits in cell culture. There were 
three observers for each assessment, and each assessment (including induced-differentiation and 
histologic analysis) was performed in duplicate. We then analyzed the mechanism of the 
difference of osteogenic differentiation potency using the MDM2-specific inhibitor Nutlin-3 at 
various concentrations. 
Results In terms of adipogenic differentiation potency, contrary to our expectations, more fatty 
acid droplets were observed in MSCs derived from normal fat than in MSCs derived from 
 ALT/WDL, although we found no significant difference between MSCs derived from 
ALT/WDL and MSCs derived from normal fat; the mean differentiation potency values (normal 
adipose tissue versus ALT/WDL) (± SD) were 0.34 (SD, ± 0.13; 95% CI, 0.24-0.44) versus 0.25 
(SD, ± 0.10; 95% CI 0.18-0.33; p = 0.22). By contrast, we found greater osteogenic 
differentiation potency in MSCs derived from ALT/WDL than in MSCs derived from normal fat. 
The mean differentiation potency values (normal adipose tissue versus ALT/WDL) (±SD) based 
on ALP staining was 1.00 versus 17 (SD, ± 35.8; 95% CI, -2.83 to 37.67; p = 0.04) with a 
medium effect size (d = 0.65). However, we found no differences based on alizarin red S 
staining; mean differentiation potency value (normal adipose tissue versus ALT/WDL) (± SD) 
was 1.00 versus 4.24 (SD, ± 4.75; 95% CI, 1.30-7.18; p = 0.58). The gap of osteogenic 
differentiation potency between MSCs from normal adipose tissue and ALT/WDL was 
decreased as MDM2-inhibitor Nutlin-3 concentration increased; the mean differentiation potency 
values (normal adipose tissue versus ALT/WDL) (± SD) based on ALP staining in each Nutlin-3 
concentrations (0, 0.625, 1.25, 2.5, 5, and 10 µmol/L) were 1.00 versus 15 (SD, ± 6.30; 95% CI, 
9.79-20.83; p = 0.001) with a large effect size (d = 3.66), 0.66 (SD, ± 0.28; 95% CI, 0.42-0.91) 
versus 4.38 (SD, ± 1.95; 95% CI, 2.67-6.08; p = 0.003) with a large effect size (d = 2.66), 0.71 
(SD, ± 0.71; 95% CI, 0.09-1.33) versus 2.96 (SD, ± 1.90; 95% CI, 1.30-4.62; p = 0.038) with a 
large effect size (d = 1.57), 0.40 (SD, ± 0.28; 95% CI, 0.16-0.65) versus 1.05 (SD, ± 0.73; 95% 
CI, 0.41-1.70; p = 0.100), 0.14 (SD, ± 0.18; 95% CI, -0.01 to 0.30) versus 1.41 (SD, ± 1.13; 95% 
CI, 0.41-2.40; p = 0.039) with a large effect size (d = 1.57), and 0.39 (SD, ± 0.61; 95% CI, -0.14 
to 0.93) versus 0.38 (SD, ± 0.47; 95% CI, -0.04 to 0.79; p = 0.963). 
Conclusions In adipogenic differentiation, contrary to our expectations,  more fatty acid droplets 
were observed in MSCs derived from normal fat than in MSCs derived from ALT/WDL, 
 although we found no significant difference in quantitative assessment using spectrometry. In 
osteogenic differentiation, as expected, MSCs derived from ALT/WDL had higher 
differentiation potency than MSCs derived from normal adipose tissue. The gap of osteogenic 
differentiation potency based on ALP staining between MSCs derived from ALT/WDL and 
MSCs derived from normal fat disappeared as Nutlin-3 concentration increased, suggesting that 
greater osteogenic differentiation could be caused by amplified MDM2 in ALT/WDL. Future 
laboratory studies might mechanistically confirm the gene and protein expression, and based on 
the mechanism of the gap of differentiation potency, if p53 contrast between MSCs in tumor and 
normal tissue could be enhanced by some stimulation (such as medicine or radiation which 
encourage p53 expression), less-toxic and more-effective differentiation therapy to MSCs in 
malignancies might be developed. 
Clinical Relevance Because osteogenic differentiation potency was higher in MSCs derived from 
ALT/WDL, future studies might investigate whether tumors with amplified MDM2 could be 
treated more effectively by osteogenic differentiation-induced therapy.  
  
Introduction 
Mesenchymal stem cells (MSCs), present in the bone marrow, adipose tissue, and other various 
tissues, can differentiate into other mesenchymal cells such as adipocyte, osteoblast, and 
chondrocyte cells. Cancer stem cells derived from mutant MSCs are involved with tumorigenesis, 
metastasis, and chemoresistance [14]. Considering the failures of conventional therapeutic 
approaches, novel treatment methods targeting MSCs in malignancies are needed. TP53 
mutation, a cancer-regulating gene that codes for a protein that regulates the cell cycle and hence 
functions as a tumor suppressor, is the most-frequently occurring gene abnormality in human 
malignant neoplasias [4-6, 11, 15, 18, 19, 22]. The p53 protein gene product in MSCs regulates 
differentiation into osteogenic or adipogenic lineages by suppressing osterix, runx, and pparγ 
genes in MSCs [10, 16, 17], and p53 function is depressed in most malignancies [9].  
If MSCs in malignancies similarly show a p53 hypofunction, differentiation therapy into 
osteogenic or adipogenic lineages may be an effective treatment method, suppressing the toxicity 
on the basis of the gap of differentiation potency between MSCs in malignancy and normal 
tissue. We therefore wished to begin to explore this idea by evaluating atypical lipomatous 
tumor/well-differentiated liposarcoma (ALT/WDL) cells, because murine double minute 2 
(MDM2) gene amplification, which leads to p53 hypofunction, is found in almost all 
ALT/WDLs [7, 21]. To our knowledge, there are no studies that have investigated the 
differentiation potency of MSCs derived from ALT/WDL.  
We therefore sought to compare osteogenic and adipogenic differentiation potency between 
MSCs isolated and cultured from normal adipose tissue and ALT/WDL cells in the same patients.  
Patients and Methods 
 We compared osteogenic and adipogenic differentiation potency between MSCs isolated and 
cultured from normal adipose tissues and ALT/WDLs form the same patients (Fig. 1). We made 
the comparisons using quantitative or semiquantitative histologic techniques.  
During tumor resections in six patients with ALT/WDL, we analyzed 3 ml
 
of tumor, and for the 
comparison, we harvested a similar amount of normal-appearing subcutaneous adipose tissue 
from an area remote from the tumor. The study group included five men and one woman, with a 
mean age of 58 ± 7 years and mean BMI of 26 ± 3 kg/m
2
. The patients did not have diabetes or 
severe systemic illnesses, and none were taking medications that were known to affect the 
adipose tissue mass or metabolism. The study protocol was approved by the ethical committees 
at our respective universities. All patients provided written informed consent.  
The MDM2 copy numbers of ALT/WDL tissues of six patients were analyzed with TaqMan
®
 
Copy Number Assays (Catalog Number: 4400291, assay number: Hs02873318_cn; Applied 
Biosystems, Foster City, CA, USA). Genomic DNA (gDNA) from formalin-fixed paraffin-
embedded ALT/WDL tissues was isolated using DNeasy kits (Qiagen, Hamburg, Germany). 
gDNA concentrations were determined by A260 measurements (NanoDrop; Thermo Scientific, 
Wilmington, DE, USA), and purity was measured by A260/A280 measurement (all gDNA 
samples were > 1.70). The TaqMan
®
 copy number reference assay (Applied Biosystems 
4403326) and the TaqMan
®
 copy number assay (Applied Biosystems 4400291, Assay ID 
Hs02873318_cn) were used according to the manufacturer’s instructions. Real-time quantitative 
PCR was performed using the StepOne™ Real Time PCR system (Applied Biosystems). 
Thermocycling conditions were 95° C for 10 minutes followed by 40 cycles of 95° C for 
15 seconds and 60° C for 60 seconds. Quantification was performed using the ΔΔCt method in 
triplicate.  
 The CopyCaller software v2.0 (Applied Biosystems) was used to perform the copy number 
analysis. In ALT/WDL tissues of all six patients, the copy number of the MDM2 gene was 
greater than 3 (mean = 6). Human MSCs were isolated as previously described [8], with minor 
modifications. We used adipose-derived stem cells (ADSC) or dedifferentiated fat cells (DFAT) 
as MSCs. Tissues from three patients were examined using ADSC, and the other three were 
examined using DFAT. Fat tissue fragments were minced using scissors and were digested in 
0.12% collagenase type I medium with gentle shaking at 37° C for 45 minutes. The resulting 
material was centrifuged at 1300 rpm for 6 minutes at room temperature, resulting in adipocytes 
and free oil being separated from the stromal vascular fraction. The floating fraction comprising 
pure isolated adipocytes was placed in an inverted 25-cm
2
 culture flask that was completely 
filled with a culture medium (Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% 
fetal bovine serum, 100 units/mL penicillin, and 0.1 mg/mL streptomycin). The primary MSCs 
grown at the top of the inverted flask were cultured for 7 days after which the flask was reversed. 
The culture medium was changed every 3 days until the cultures reached confluence (defined as 
DFAT passage 0). In contrast, the stromal vascular fraction was filtered through a 100-µm mesh 
and centrifuged at 1300 rpm for 6 minutes at room temperature and then resuspended in the 
culture medium (defined as ADSC passage 0). The cells were used for the experiments after 
passage 3. Both cells were incubated at 37° C in 5% CO2. Because primary cells have a finite 
lifespan and limited expansion capacity, gene and protein expression analyses were not 
performed.  
To answer the question whether MSCs isolated from ALT/WDL tissue have more adipogenic 
differentiation potency than MSCs isolated from normal adipose tissue have, we compared 
histologic findings, and the amount of fat droplets was quantitatively analyzed. For adipogenic 
 differentiation, MSCs, 80,000 cells/well seeded on a 24-well plate, were induced to 
differentiation 1 day after the cells were seeded in an adipogenesis induction medium comprising 
a culture medium supplemented with 1 μmol/L dexamethasone, 0.5 mmol/L 3-isobutyl-1-methyl 
xanthine (both from Millipore, Billerica, MA, USA), 10 µg/mL human insulin, and 100 µmol/L 
indomethacin (both from Sigma-Aldrich, St Louis, MO, USA). The medium was replaced every 
2 to 3 days for 21 days. Adipogenic differentiation capacities were examined using Oil Red O 
(Wako Pure Chemical Industries, Ltd, Osaka, Japan) staining at the end of the 21-day induction 
with the adipogenic differentiation medium. Cells in the 24-well plate were fixed with 10% 
formalin neutral buffer solution, and their triacylglycerol content was stained with 0.3% (wt/vol) 
Oil Red O in 60% (vol/vol) isopropanol. After repeatedly washing with water, the stained Oil 
Red O was extracted with 100% (vol/vol) isopropanol. The absorbance of the extracted Oil Red 
O was spectrophotometrically determined at 520 nm to measure triglyceride accumulation.  
To answer the question whether MSCs isolated from ALT/WDL tissue have more osteogenic 
differentiation potency than MSCs isolated from normal adipose tissue, we compared histologic 
findings and the amount of stains related to osteogenic differentiation were semiquantitatively 
analyzed. Differentiation into osteoblasts was induced using an osteoblast-inducer reagent, 
according to the manufacturer’s instructions. MSCs isolated from normal adipose tissue and 
ALT/WDL were seeded in a density of 5000 cells/cm
2
 on a 12-well plate. The MSCs were 
induced to osteoblast differentiation after 1 day in an osteogenesis induction medium. The 
osteogenesis induction medium was replaced every 4 days for 14 days in ALP staining assays 
and for 28 days in alizarin red S staining assays. ALP and alizarin red S staining were performed 
according to the manufacturer’s instructions. ALP is related to preosseous cellular metabolism, 
and alizarin red S is related to calcium deposits in cell culture. Macrophotographs were taken on 
 the TREVIEWER (Trytec, Kyoto, Japan), a high-quality LED light box, after which osteogenic 
differentiation potency was assessed by measuring a specific colored area using the Image J 
(National Institutes of Health, Bethesda, MD, USA; http://rsbweb.nih.gov/ij/) image analysis 
software. The osteoblast-inducer reagent (Cat. No. MK430) was obtained from Takara Bio Inc 
(Dairen, China). An ALP staining kit was obtained from CosmoBio. (Tokyo, Japan), and the 
alizarin red S staining kit was purchased from ScienCell Research Laboratories (San Diego, CA, 
USA).  
To answer the question whether the gap of osteogenic differentiation capacity occurs as a result 
of depressed p53 activity because of MDM2 amplification, we used the MDM2 inhibitor Nutlin-
3. Both MSCs were induced into osteogenic differentiation with the osteogenesis induction 
medium supplemented with Nutlin-3 in the following concentrations: 10, 5, 2.5, 1.25, 0.625, and 
0 µmol. Osteogenic differentiation capacity was assessed as previously mentioned. The MDM2 
inhibitor Nutlin-3 was obtained from Santa Cruz Biotech (Santa Cruz, CA, USA). 
Statistical Analysis 
Data are presented as mean ± SD. Adipogenic differentiation comparisons between the values 
were performed using the two-tailed Student’s t-test. For effect sizes we calculated Pearson’s 
correlation coefficient r and used three levels: small (0.1), medium (0.3), or large (0.5). 
Osteogenic differentiation potency was assessed by ALP and alizarin red S staining and then 
expressed with a ratio of the value of ALT/WDL to that of normal fat and statistically analyzed 
using the Mann-Whitney U test. For effect sizes we calculated Cohen’s d and used three levels: 
small (0.2), medium (0.5), or large (0.8). For all statistical analyses, the level of significance was 
set at a probability less than 0.05. All experiments were repeated at least twice.  
Results  
 Adipogenic Differentiation Potency 
In adipogenic differentiation potency, contrary to our expectations, more fatty acid droplets were 
observed in MSCs derived from normal fat than in MSCs derived from ALT/WDL, although we 
found no differences between MSCs derived from ALT/WDL and MSCs derived from normal 
fat; the mean differentiation potency values (normal adipose tissue versus ALT/WDL) (± SD) 
were 0.34 (SD, ± 0.13; 95% CI, 0.24-0.44) versus 0.25 (SD, 0.10; 95% CI, 0.18-0.33; p = 0.22) 
(Fig. 2).  
Osteogenic Differentiation Potency 
In osteogenic differentiation potency based on ALP staining, we found greater osteogenic 
differentiation potency in MSCs derived from ALT/WDL than in MSCs derived from normal fat; 
the mean differentiation potency values (normal adipose tissue versus ALT/WDL) (± SD) based 
on ALP staining was 1.00 versus 17 (SD, ± 35.8; 95% CI, -2.83 to 37.67; p = 0.04) with a 
medium effect size (d = 0.65) (Fig. 3). However, we found no differences based on alizarin red S 
staining; the mean differentiation potency value (normal adipose tissue versus ALT/WDL) 
(±SD) was 1.00 versus 4.24 (SD, ± 4.75; 95% CI, 1.30-7.18; p = 0.58) (Fig. 4). 
We then analyzed the mechanism of the difference of osteogenic differentiation potency using 
the MDM2-specific inhibitor Nutlin-3 at various concentrations. The gap of osteogenic 
differentiation potency between MSCs from normal adipose tissue and ALT/WDL was 
decreased as the Nutlin-3 concentration increased; the mean differentiation potency values 
(normal adipose tissue versus ALT/WDL) (±SD) based on ALP staining in each Nutlin-3 
concentration (0, 0.625, 1.25, 2.5, 5, and 10 µmol/L) was 1.00 versus 15 (SD, ± 6.30; 95% CI, 
9.79-20.83; p = 0.001) with a large effect size (d = 3.66), 0.66 (SD, ± 0.28; 95% CI, 0.42-0.91) 
versus 4.38 (SD, ± 1.95; 95% CI, 2.67-6.08; p = 0.003) with a large effect size (d = 2.66), 0.71 
 (SD, ± 0.71; 95% CI, 0.09-1.33) versus 2.96 (SD, ± 1.90; 95% CI, 1.30-4.62; p = 0.038) with a 
large effect size (d = 1.57), 0.40 (SD, ± 0.28; 95% CI, 0.16-0.65) versus 1.05 (SD, ± 0.73; 95% 
CI, 0.41-1.70; p = 0.100), 0.14 (SD, ± 0.18; 95% CI, -0.01 to 0.30) versus 1.41 (SD, ± 1.13; 95% 
CI, 0.41-2.40; p = 0.039) with a large effect size (d = 1.57), and 0.39 (SD, ± 0.61; 95% CI, -0.14 
to 0.93) versus 0.38 (SD, ± 0.47; 95% CI, -0.04 to 0.79; p = 0.963) (Fig. 5). 
Discussion 
The p53 protein in MSCs regulates differentiation into osteogenic or adipogenic lineage. 
Because p53 function is depressed in most malignancies, if MSCs in malignancies also have p53 
hypofunction, differentiation therapy into osteogenic or adipogenic lineage may be an effective 
treatment. To the best of our knowledge, there are no studies that have investigated the 
differentiation potency of MSCs derived from ALT/WDL. Therefore, we compared osteogenic 
and adipogenic differentiation potency between MSCs isolated and cultured from normal adipose 
tissue and ALT/WDL from the same patients. We selected ALT/WDL for testing the hypothesis 
that MSCs derived from the tumors, which have depressed p53 function, will be introduced into 
adipogenic or osteogenic differentiation more than MSCs derived from normal tissue because 
ALT/WDL has a relevant counterpart, which is normal adipose tissue. ALT/WDL is used in 
research because it has a low prevalence of p53 mutation and high prevalence of MDM2 
amplification [13]. Even if ALT/WDLs have TP53 missense mutations in this study, the 
resulting p53 hypofunction should lead MSCs to the same tendency of differentiation as MDM2 
amplified tumors. 
Some limitations exist in this study. First, there is considerable discussion regarding whether 
adipose-derived MSCs are a pure or mixed population. Using two kinds of isolation, we assessed 
all cells that adhere to a plastic flask and that have proliferative and differentiation capacities. 
 Each comparison was performed with the cells isolated using the same method. Second, we did 
not perform gene and protein expression experiments because of the difficulty in primary 
culturing of MSCs derived from ALT/WDL, which has relatively low prevalence. Puzio-Kuter et 
al. [12] reportedthat using a liposarcoma mouse model with the conditional inactivation of PTEN 
and p53, MDM2 RNA levels by real-time PCR (T TaqMan
®
) in normal versus tumor tissue were 
1.5- to twofold (data not shown) as observed in human liposarcoma samples, and the protein 
expression of MDM2 by immunohistochemistry was at very high levels in WDL sections in 
areas with clear lipoblasts. Although that was a special setting, they provided useful information 
in terms of amplified MDM2 expression in liposarcoma. Third, the sample harvesting sites were 
different between normal adipose tissues and ALT/WDLs. We harvested the comparison samples 
from the same human to equalize the background in each comparison. However, most 
ALT/WDLs were deep (below the fascia), and normal adipose tissues were harvested from 
subcutaneous tissues in this study. We do not believe that this is a disqualifying limitation 
because the amplified MDM2 copy numbers of ALT/WDL tissues of six patients were 
confirmed, indicating, we believe, that we have made a fair comparison between normal and 
tumor tissues.  
In adipogenic differentiation, contrary to our expectations, we found no differences between 
MSCs derived from ALT/WDL and MSCs derived from normal fat. Gopinathan et al. [2] 
reported MDM2 regulates peroxisome proliferator-activated receptor-α (PPARα)-mediated 
pathways of lipid metabolism. Moreover, Goto et al. [3] reported that the activation of PPARα 
stimulates differentiation and fatty acid oxidation in adipocytes. Because our study focused on 
the relationship between MDM2 and p53, adipogenic induced-differentiation was not suitable. 
Considering differentiation therapy, in at least tumors that have depressed p53 function because 
 of MDM2 amplification, adipogenic-induced differentiation may be ineffective. Demetri et al. 
[1] and Tontonoz et al. [20] reported induction of human liposarcoma terminal differentiation by 
the PPAR- γ ligand troglitazone as a potential therapeutic method. According to our observations, 
those adipogenic-differentiation-inducing methods may be inefficient in tumors with MDM2 
amplification, although terminal differentiation of tumor cells is promising in terms of 
suppressing the tumor growth and metastasis.  
In osteogenic differentiation, as expected, MSCs derived from ALT/WDL had higher 
differentiation potency than MSCs derived from normal adipose tissue. To the best of our 
knowledge, no studies have compared the differentiation potency between those MSCs. Because 
the difference of osteogenic differentiation potency disappeared as Nutlin-3 concentration 
increased, the difference can be attributed to MDM2 amplification, which leads to depressed p53 
function in MSCs derived from ALT/WDL, although we have not confirmed their gene 
expressions. The osteogenic differentiation capacity was not proportional to the MDM2 
amplification copy number. We believe the reason for this is that the copy number was assayed 
with formalin-fixed paraffin-embedded ALT/WDL tissues including normal various cells and the 
copy number is the mean of the tissue. Therefore, the copy number is not an accurate number of 
MDM2 amplified cells.  
Previous studies revealed that ALT/WDL tumors have increased MDM2 expression [7, 21]. In 
the current study, we found that MSCs derived from ALT/WDL tissues have more osteogenic 
differentiation potency, than MSCs derived from the normal adipose tissue of the same human. 
The gap of osteogenic differentiation potency between MSCs derived from ALT/WDL and 
normal adipose tissues was depressed by the MDM2 inhibitor Nutlin-3. Future laboratory studies 
might mechanistically confirm the gene and protein expressions, and based on the mechanism of 
 the gap of differentiation potency, if p53 contrast between MSCs in tumor and normal tissue 
could be enhanced by some stimulation (such as treatments that encourage p53 expression), less-
toxic and more-effective differentiation therapy to MSCs in malignancies might be developed. If 
future studies confirm osteogenic differentiation potency is higher in MSCs derived from 
ALT/WDL, and can confirm the mechanism behind this observation, then translational work 
might subsequently investigate whether tumors with amplified MDM2 could be treated more 
effectively by osteogenic differentiation-induced therapy with adjuvant chemotherapy or 
radiotherapy.  
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 Legends 
Fig. 1 Dedifferentiated fat cells were isolated as follows: Fat tissue fragments were minced 
using scissors (1), and were digested in 0.12% collagenase type I medium (2). The resulting 
material was centrifuged (3). The floating fraction was placed in an inverted culture flask that 
was completely filled with culture medium (4). After 7 days, the flask was reversed (5).  
Adipose-derived stem cells were isolated the same as dedifferentiated fat cells (1, 2, and 3). The 
stromal vascular fraction was filtered through a 100-µm mesh and centrifuged and then 
resuspended in a culture medium (6).  
Fig. 2A-C (A) A photomicrograph shows MSC derived from normal fat after 21 days of induced 
adipogenic differentiation. Fat droplets in the cells were stained with 0.3% (wt/vol) Oil Red O in 
60% (vol/vol) isopropanol.(B) A photomicrograph shows MSC derived from ALT/WDL after 21 
days of induced adipogenic differentiation. Fat droplets in the cells were stained with 0.3% 
(wt/vol) Oil Red O in 60% (vol/vol) isopropanol. . 
(C) A graph shows the adipogenic differentiation ability of MSCs derived from normal fat and 
ALT/WDL. The stained droplets were extracted with 100% (vol/vol) isopropanol. The 
absorbance was spectrophotometrically determined at 520 nm. We found no significant 
differences between MSCs derived from ALT/WDL and MSCs derived from normal fat. 
Fig. 3A-C (A) A photomicrograph shows MSC derived from normal fat after 14 days of induced 
osteogenic differentiation. ALP staining was performed. 
(B) A photomicrograph shows MSC derived from ALT/WDL after 14 days of induced 
osteogenic differentiation. ALP staining was performed.  
Greater ALP staining was observed in MSC derived from ALT/WDL. 
 (C) A graph shows the osteogenic differentiation ability of MSCs derived from normal fat and 
ALT/WDL using ALP staining. Osteogenic differentiation potency was assessed by measuring a 
specific colored area using the Image J image analysis software. MSCs derived from ALT/WDL 
had higher differentiation potency than MSCs derived from normal adipose tissue.  
 Fig. 4A-C  (A) A photomicrograph shows MSC derived from normal fat after 28 days of 
induced osteogenic differentiation. Alizarin red S staining was performed. 
(B) A photomicrograph shows MSC derived from ALT/WDL after 28 days of induced 
osteogenic differentiation. Alizarin red S staining was performed.  
Greater calcium deposition was observed in MSC derived from ALT/WDL. 
(C) A graph shows the osteogenic differentiation ability of MSCs derived from normal fat and 
ALT/WDL using Alizarin red S staining. Osteogenic differentiation potency was assessed by 
measuring a specific colored area using the Image J image analysis software. We found no 
significant differences between MSCs derived from ALT/WDL and MSCs derived from normal 
fat. 
Fig. 5A-C (A) Photomicrographs show MSCs derived from normal fat after 14 days of induced 
osteogenic differentiation with an osteogenesis induction medium supplemented with MDM2 
inhibitor Nutlin-3 in various concentrations. ALP staining was performed. 
(B) Photomicrographs show MSCs derived from ALT/WDL after 14 days of induced osteogenic 
differentiation with an osteogenesis induction medium that was supplemented with MDM2 
inhibitor Nutlin-3 in various concentrations. ALP staining was performed. 
The gap of ALP staining between MSCs from normal adipose tissue and ALT/WDL was 
decreased as the Nutlin-3 concentration increased. 
 (C) Graphs show the osteogenic differentiation ability of MSCs derived from normal fat and 
ALT/WDL using ALP staining. Osteogenic differentiation potency was assessed by measuring a 
specific colored area using the Image J image analysis software. The gap of differentiation 
potency between MSCs from normal adipose tissue and ALT/WDL was decreased as the Nutlin-
3 concentration increased. 
 
  
 
